• Je něco špatně v tomto záznamu ?

Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)

LK. Mell, I. Sirák, L. Wei, R. Tarnawski, U. Mahantshetty, CM. Yashar, MT. McHale, R. Xu, G. Honerkamp-Smith, R. Carmona, M. Wright, CW. Williamson, L. Kasaová, N. Li, S. Kry, J. Michalski, W. Bosch, W. Straube, J. Schwarz, J. Lowenstein, SB....

. 2017 ; 97 (3) : 536-545. [pub] 20161123

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031092

PURPOSE: To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced cervical cancer. METHODS AND MATERIALS: We enrolled patients with stage IB-IVA cervical carcinoma in a single-arm phase II trial involving 8 centers internationally. All patients received weekly cisplatin concurrently with once-daily IMRT, followed by intracavitary brachytherapy, as indicated. The primary endpoint was the occurrence of either acute grade ≥3 neutropenia or clinically significant GI toxicity within 30 days of completing chemoradiation therapy. A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT (IG-IMRT) would lower the risk of acute neutropenia. We also longitudinally assessed patients' changes in quality of life. RESULTS: From October 2011 to April 2015, 83 patients met the eligibility criteria and initiated protocol therapy. The median follow-up was 26.0 months. The incidence of any primary event was 26.5% (95% confidence interval [CI] 18.2%-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (P=.012). The incidence of grade ≥3 neutropenia and clinically significant GI toxicity was 19.3% (95% CI 12.2%-29.0%) and 12.0% (95% CI 6.7%-20.8%), respectively. Compared with patients treated without IG-IMRT (n=48), those treated with IG-IMRT (n=35) had a significantly lower incidence of grade ≥3 neutropenia (8.6% vs 27.1%; 2-sided χ(2)P=.035) and nonsignificantly lower incidence of grade ≥3 leukopenia (25.7% vs 41.7%; P=.13) and any grade ≥3 hematologic toxicity (31.4% vs 43.8%; P=.25). CONCLUSIONS: IMRT reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes. Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031092
003      
CZ-PrNML
005      
20171030131510.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijrobp.2016.11.027 $2 doi
035    __
$a (PubMed)28126303
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mell, Loren K $u Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California. Electronic address: lmell@ucsd.edu.
245    10
$a Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2) / $c LK. Mell, I. Sirák, L. Wei, R. Tarnawski, U. Mahantshetty, CM. Yashar, MT. McHale, R. Xu, G. Honerkamp-Smith, R. Carmona, M. Wright, CW. Williamson, L. Kasaová, N. Li, S. Kry, J. Michalski, W. Bosch, W. Straube, J. Schwarz, J. Lowenstein, SB. Jiang, CC. Saenz, S. Plaxe, J. Einck, C. Khorprasert, P. Koonings, T. Harrison, M. Shi, AJ. Mundt, . ,
520    9_
$a PURPOSE: To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced cervical cancer. METHODS AND MATERIALS: We enrolled patients with stage IB-IVA cervical carcinoma in a single-arm phase II trial involving 8 centers internationally. All patients received weekly cisplatin concurrently with once-daily IMRT, followed by intracavitary brachytherapy, as indicated. The primary endpoint was the occurrence of either acute grade ≥3 neutropenia or clinically significant GI toxicity within 30 days of completing chemoradiation therapy. A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT (IG-IMRT) would lower the risk of acute neutropenia. We also longitudinally assessed patients' changes in quality of life. RESULTS: From October 2011 to April 2015, 83 patients met the eligibility criteria and initiated protocol therapy. The median follow-up was 26.0 months. The incidence of any primary event was 26.5% (95% confidence interval [CI] 18.2%-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (P=.012). The incidence of grade ≥3 neutropenia and clinically significant GI toxicity was 19.3% (95% CI 12.2%-29.0%) and 12.0% (95% CI 6.7%-20.8%), respectively. Compared with patients treated without IG-IMRT (n=48), those treated with IG-IMRT (n=35) had a significantly lower incidence of grade ≥3 neutropenia (8.6% vs 27.1%; 2-sided χ(2)P=.035) and nonsignificantly lower incidence of grade ≥3 leukopenia (25.7% vs 41.7%; P=.13) and any grade ≥3 hematologic toxicity (31.4% vs 43.8%; P=.25). CONCLUSIONS: IMRT reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes. Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia.
650    _2
$a adenokarcinom $x diagnostické zobrazování $x patologie $x terapie $7 D000230
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    12
$a kostní dřeň $7 D001853
650    _2
$a brachyterapie $x metody $7 D001918
650    _2
$a spinocelulární karcinom $x diagnostické zobrazování $x patologie $x terapie $7 D002294
650    _2
$a chemoradioterapie $x metody $7 D059248
650    _2
$a cisplatina $x terapeutické užití $7 D002945
650    _2
$a studie proveditelnosti $7 D005240
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální trakt $x účinky záření $7 D041981
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neutropenie $x epidemiologie $x prevence a kontrola $7 D009503
650    _2
$a léčba šetřící orgány $x metody $7 D059351
650    _2
$a radiosenzibilizující látky $x terapeutické užití $7 D011838
650    _2
$a celková dávka radioterapie $7 D011879
650    _2
$a radioterapie řízená obrazem $x metody $7 D061089
650    _2
$a radioterapie s modulovanou intenzitou $x metody $7 D050397
650    _2
$a nádory děložního čípku $x diagnostické zobrazování $x patologie $x terapie $7 D002583
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Sirák, Igor $u Department of Oncology and Radiotherapy, University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Wei, Lichun $u Xijing Hospital, Xian, China.
700    1_
$a Tarnawski, Rafal $u Marie Sklodowska Cancer Center and Institute of Oncology, Gliwice, Poland.
700    1_
$a Mahantshetty, Umesh $u Tata Memorial Centre, Parel, Mumbai, India.
700    1_
$a Yashar, Catheryn M $u Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
700    1_
$a McHale, Michael T $u University of California, San Diego, La Jolla, California.
700    1_
$a Xu, Ronghui $u University of California, San Diego, La Jolla, California.
700    1_
$a Honerkamp-Smith, Gordon $u University of California, San Diego, La Jolla, California.
700    1_
$a Carmona, Ruben $u University of California, San Diego, La Jolla, California.
700    1_
$a Wright, Mary $u University of California, San Diego, La Jolla, California.
700    1_
$a Williamson, Casey W $u Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
700    1_
$a Kasaová, Linda $u Department of Oncology and Radiotherapy, University Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Li, Nan $u Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
700    1_
$a Kry, Stephen $u Department of Radiation Oncology, Washington University, St Louis, Missouri.
700    1_
$a Michalski, Jeff $u MD Anderson Cancer Center, Houston, Texas.
700    1_
$a Bosch, Walter $u MD Anderson Cancer Center, Houston, Texas.
700    1_
$a Straube, William $u MD Anderson Cancer Center, Houston, Texas.
700    1_
$a Schwarz, Julie $u Washington University, St Louis, Missouri.
700    1_
$a Lowenstein, Jessica $u University of California, San Diego, La Jolla, California.
700    1_
$a Jiang, Steve B $u University of California, San Diego, La Jolla, California.
700    1_
$a Saenz, Cheryl C $u University of California, San Diego, La Jolla, California.
700    1_
$a Plaxe, Steve $u University of California, San Diego, La Jolla, California.
700    1_
$a Einck, John $u Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
700    1_
$a Khorprasert, Chonlakiet $u Kaiser Permanente Medical Center, San Diego, California.
700    1_
$a Koonings, Paul $u Chulalongkorn Hospital, Bangkok, Thailand.
700    1_
$a Harrison, Terry $u Chulalongkorn Hospital, Bangkok, Thailand.
700    1_
$a Shi, Mei $u Xijing Hospital, Xian, China.
700    1_
$a Mundt, A J $u Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California.
700    1_
$a ,
773    0_
$w MED00002371 $t International journal of radiation oncology, biology, physics $x 1879-355X $g Roč. 97, č. 3 (2017), s. 536-545
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28126303 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171030131559 $b ABA008
999    __
$a ok $b bmc $g 1254685 $s 992119
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 97 $c 3 $d 536-545 $e 20161123 $i 1879-355X $m International journal of radiation oncology, biology, physics $n Int J Radiat Oncol Biol Phys $x MED00002371
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace